Penumbra Q3 revenue $270.9M (+26.8% YoY); raises full-year revenue guidance to $1.05B-$1.07B

Penumbra Inc

2023-Q3 EPS reported $0.94 revenue$773,843,000

Revenue $270.9M (+26.8% YoY, +25.9% constant currency); thrombectomy products revenue $179.1M (+38.0% YoY).
Income from operations $12.6M; non-GAAP income from operations $33.2M. Net income $9.2M; adjusted EBITDA $51.5M (19.0% margin).
Gross margin improved to 65.6% from 63.3% YoY, driven by favorable product mix and higher volume.
Recorded $18.2M one-time expense for acquired IPR&D; total operating expenses 60.9% of revenue.
Q4 2023 revenue growth expected 28%-31% YoY; full year 2023 revenue guidance raised to $1.05B-$1.07B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Penumbra Inc reported the third quarter ended September 30, 2023 results: revenue $270.9 million, net income $9.2 million.

Period: the third quarter ended September 30, 2023
Revenue: $270.9 million
Net income: $9.2 million
Result: reported results

Exact text from the filing

Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $270.9 million in the third quarter of 2023, an increase of 26.8% or 25.9% in constant currency 1 , compared to the third quarter of 2022. • Revenue of $179.1 million from sales of our

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-23-000126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.